A new drug in the United States has been shown to be quite effective against U=coronavirus. It has almost halved the risk of hospitalization and death and has given new hope to the global fight against the COVID-19 pandemic.
Washington: A new drug from America has proved to be very effective in the treatment of corona virus. Merck & Co.’s oral drug molnupiravir could reduce the death or need for hospitalization of critically ill COVID-19 patients by 50 percent.
On Friday, the company claimed that the results of this oral drug in interim clinical trials have turned out to be very good. The company said in a statement that it plans to seek emergency approval for the drug in the US as soon as possible.
An interim analysis of a phase-3 study based on 775 trial participants found that 7.3 percent of patients treated with mollupiravir were hospitalized within 29 days. Of the patients who received the placebo, 14.1 percent were hospitalized or died within 29 days.
No deaths occurred in given patients molanupiravir Within a 29-day period, eight deaths occurred in placebo-treated patients.
The efficacy of the drug was not affected by the time of onset of symptoms or the underlying risk factor. Furthermore, based on available viral sequencing data (approximately 40 percent of participants), molanupivir demonstrated consistent efficacy in the viral variants gamma, delta and mu.
“With its promising results, we are hopeful that molnupiravir could become an important drug as part of the global effort to fight the coronavirus pandemic,” Merck CEO and President Robert M Davis said in a statement.
Phase 3 trials have been conducted at more than 170 sites in countries including the United States (US), Brazil, Italy, Japan, South Africa, Taiwan and Guatemala. molanupiraviri SARS-CoV-2 has also been shown to be active in several preclinical models.
These include prophylaxis, treatment and prevention of transmission. therefore it is believed that molanupiravir May be the first oral antiviral drug to treat coronavirus.
First published:October 1, 2021, 9:47 pm